We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How to use a quasi-experimental study to evaluate your digital health product.
What qualifies as ordinary commuting and private travel for tax purposes.
How to use A/B testing to evaluate your digital health product.
Use the case studies to help you decide when your goods may (or may not) go beyond insufficient production.
This guidance relates to Standard Essential Patents licensing.
A collection of Fast Forward Competition case studies.
Why it's important to evaluate digital health products that have been developed rapidly and how to choose evaluation methods in these circumstances.
An overview of the work the IPO is undertaking in relation to Standard Essential Patents.
Sections (48B.01 - 48B.17) last updated: July 2021.
How to use a cost effectiveness analysis to evaluate your digital health product.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).